EPA and DHA Market Size and Share Analysis - Growth Trends and Forecasts (2026-2033)

Market Size and Trends

The EPA and DHA market is estimated to be valued at USD 4.7 billion in 2026 and is expected to reach USD 8.9 billion by 2033, growing at a compound annual growth rate (CAGR) of 9.3% from 2026 to 2033. This robust growth reflects increasing consumer awareness about the health benefits of omega-3 fatty acids, driving demand across dietary supplements, functional foods, and pharmaceuticals. The expanding elderly population and rising prevalence of cardiovascular and cognitive disorders further fuel market expansion globally.

Market trends indicate a significant shift towards sustainable and plant-based sources of EPA and DHA, driven by environmental concerns and consumer preference for eco-friendly products. Additionally, technological advancements in extraction and purification methods are enhancing product quality and bioavailability. The integration of these omega-3 fatty acids into personalized nutrition and preventive healthcare strategies is gaining traction. Moreover, regulatory support and increasing investments in R&D are reinforcing innovation and market penetration across developed and emerging economies.

Segmental Analysis:

By Product Type: Dominance of EPA Omega-3 Driven by Cardiovascular and Cognitive Health Benefits

In terms of By Product Type, EPA Omega-3 contributes the highest share of the EPA and DHA market owning to its well-documented benefits in cardiovascular health, anti-inflammatory properties, and mental wellness. EPA (Eicosapentaenoic Acid) plays a critical role in reducing the risk of heart disease by helping to lower blood triglyceride levels and supporting healthy blood vessel function. Increasing awareness among consumers about heart-related conditions and the preventive potential of EPA Omega-3 supplements fuels demand. Furthermore, EPA's anti-inflammatory effects make it highly sought after not only in traditional health supplements but also in clinical nutrition, particularly for patients dealing with chronic inflammatory diseases. The rising prevalence of lifestyle-related disorders encourages healthcare professionals to recommend EPA Omega-3 as a natural adjunct, enhancing its market penetration. Additionally, EPA Omega-3's emerging role in mental health, particularly in managing depression and anxiety symptoms, bolsters its positioning. Scientific endorsements and growing consumer preference for natural, bioactive compounds enhance the trust and uptake of EPA-focused products. The EPA Omega-3 segment also benefits from product innovation that targets specific health conditions, enabling manufacturers to diversify offerings and cater to varying consumer needs, from general wellness to targeted therapeutic use. Collectively, these factors contribute to the dominance of EPA Omega-3 within the product type classification of the EPA and DHA market.

By Source: Fish Oil's Market Leadership Fueled by Accessibility and Established Supply Chains

In terms of By Source, Fish Oil holds the highest share in the EPA and DHA market due to its long-established reputation, cost-effectiveness, and widespread availability. Fish oil remains the primary source of omega-3 fatty acids because it contains a natural and balanced concentration of EPA and DHA, making it a favored choice among manufacturers and consumers alike. The mature supply chains and extensive processing infrastructure around fish oil facilitate large-scale production that meets global demand efficiently. Furthermore, consumer familiarity with fish oil supplements and their benefits contributes to a higher adoption rate compared to alternative sources. Technological advancements aimed at improving the purity, odor control, and concentration levels of fish oil have addressed earlier concerns related to taste and quality, making these products more appealing. Environmental sustainability practices, such as responsible fishing methods and certification programs, are increasingly embraced within the fish oil segment, which strengthens consumer confidence and market stability. While alternatives like krill oil and algal oil are gaining attention for niche applications and specific preferences, their higher production costs and still-developing supply chains limit their overall market share. The combination of accessibility, consumer trust, and ongoing improvements cements fish oil's leadership position as the primary source in the EPA and DHA market.

By Application: Pharmaceuticals Lead Due to Therapeutic Validation and Regulatory Support

In terms of By Application, Pharmaceuticals represent the largest segment within the EPA and DHA market, driven by the recognized therapeutic efficacy and strong regulatory endorsements of omega-3s in medical treatments. EPA and DHA are increasingly incorporated into prescription medications, particularly for managing hypertriglyceridemia, cardiovascular diseases, and inflammatory disorders, where clinical evidence supports their use either as standalone therapy or in combination with other drugs. The growing burden of non-communicable diseases worldwide highlights the need for effective, evidence-based pharmaceutical interventions, positioning omega-3 enriched drugs as vital components of treatment regimens. Regulatory approvals and recommendations by health authorities have enabled pharmaceutical formulations of EPA and DHA to gain widespread acceptance among healthcare professionals, ensuring integration into healthcare protocols. Moreover, ongoing research continues to unveil new applications, such as cognitive impairment and mental health disorders, further expanding pharmaceutical demand. The pharmaceutical segment benefits from product standardization, higher quality control, and dosage precision, enhancing patient adherence and therapeutic outcomes. Additionally, investment by pharmaceutical companies in R&D and clinical trials solidifies the credibility of EPA and DHA products in this domain. Collectively, these factors drive the pharmaceutical segment's leadership by blending scientific validation, regulatory compliance, and critical health applications of EPA and DHA.

Regional Insights:

Dominating Region: North America

In North America, the EPA and DHA market holds a dominant position driven by a well-established healthcare infrastructure and high consumer awareness regarding the health benefits of omega-3 fatty acids. The region benefits from stringent government regulations ensuring the quality and safety of dietary supplements, which enhances consumer trust. The presence of several multinational corporations specializing in nutritional supplements—such as Pfizer (with its Omega-3 prescription products), Amarin Corporation, and Omega Protein Corporation—furthers market consolidation. Furthermore, the region's advanced supply chain ecosystem facilitates efficient distribution through pharmacies, health stores, and e-commerce channels. Trade dynamics also favor North America due to favorable import regulations and access to sustainably sourced marine ingredients.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific exhibits the fastest growth in the EPA and DHA market, driven by rising disposable incomes, increasing health awareness, and rapidly expanding health and wellness sectors in countries like China, India, Japan, and Australia. Governments in this region have been actively promoting nutritional health through public campaigns and regulations encouraging fortification and supplementation. The burgeoning middle-class population and increasing urbanization have led to shifts toward preventive healthcare, supporting demand for omega-3 enriched products. Local companies such as Zhejiang NHU Co., Ltd. (China) and TCI Co., Ltd. (Japan), alongside international players entering the market, are contributing to regional expansion. Trade importance is underscored by increasing imports of marine oils and plant-based omega-3 sources, while regional supply chains are evolving rapidly to meet growing consumer needs.

EPA and DHA Market Outlook for Key Countries

United States

The United States market remains a leader in EPA and DHA consumption due to high consumer health consciousness and the influence of healthcare provider recommendations. Major players like Pfizer, Amarin Corporation, and Nordic Naturals have dedicated significant resources to product innovation and clinical research, setting industry standards. The presence of robust regulatory frameworks from the FDA ensures product reliability, which further encourages consumer adoption through both OTC supplements and prescription formulations. Additionally, diverse retail channels and growing e-commerce penetration facilitate widespread accessibility.

China

China's market for EPA and DHA is expanding swiftly, fueled by rising urbanization and shifts toward healthier diets. Government initiatives incentivizing nutritional supplements and public health awareness campaigns are critical growth drivers. Local manufacturers such as Zhejiang NHU have stepped up production capabilities, focusing on quality improvements and product diversification. Multinational companies are also actively investing in China to tap into the growing customer base, strategically entering partnerships to navigate regulatory complexities and distribution networks. Imports of omega-3 oils and ingredients have surged, reflecting growing demand and trade ties with resource-rich countries.

Japan

Japan continues to lead the Asia Pacific region in market maturity for EPA and DHA supplements, supported by one of the world's highest levels of health awareness among consumers. The government's positive stance on supplementation in elderly nutrition and preventive health has formed a supportive regulatory environment. Japanese companies like TCI Co., Ltd. and FUJIFILM Holdings have been instrumental in driving innovation, focusing on high-purity and sustainably sourced products that align with local consumer preferences. Distribution channels are well-developed, with integration of these supplements within both traditional retail and healthcare systems.

India

India's EPA and DHA market is witnessing rapid expansion due to increasing consumer awareness regarding cardiovascular and cognitive health benefits. The government's efforts to promote nutritional health combined with rising disposable incomes and a growing middle class have encouraged market entry from both domestic firms and global players. Companies such as Herbalife and Patanjali Ayurved have introduced omega-3 products, augmenting consumer choices and market penetration. Distribution remains a challenge in rural regions, but growing e-commerce platforms are mitigating accessibility issues, supporting market growth.

Australia

Australia presents a mature and sophisticated EPA and DHA market marked by elevated health awareness and strong government advocacy for nutritional supplementation. Local companies such as Blackmores and Swisse Wellness hold significant market shares, leveraging their strong brand presence and commitment to sustainable sourcing practices. The country's regulatory framework ensures product safety and quality, which bolsters consumer confidence. Australia's strategic geographic position also facilitates trade within the Asia Pacific, enabling efficient import and export flows of marine oils and novel omega-3 ingredients, promoting ongoing market development.

Market Report Scope

Market Segmentation

Product Type Insights (Revenue, USD, 2021 - 2033)

• EPA Omega-3
• DHA Omega-3
• EPA+DHA Combination
• Others

Source Insights (Revenue, USD, 2021 - 2033)

• Fish Oil
• Krill Oil
• Algal Oil
• Others

Application Insights (Revenue, USD, 2021 - 2033)

• Pharmaceuticals
• Dietary Supplements
• Infant Formulas
• Functional Foods & Beverages
• Others

Regional Insights (Revenue, USD, 2021 - 2033)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• DSM Nutritional Products
• BASF SE
• Croda International Plc
• Neptune Wellness Solutions Inc.
• Polaris Corporation
• Aker BioMarine AS
• Lysi hf
• GC Rieber Oils AS
• Ingredion Incorporated
• Lonza Group Ltd.
• Omega Protein Corporation
• EPAX AS
• BioProcess Algae LLC
• Zhejiang NHU Co. Ltd.
• Zhejiang Zheneng Biopharma Co. Ltd.
• Ocean Nutrition Canada Ltd.
• Cargill, Incorporated